Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.

@article{Meier2004SecretionDA,
  title={Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.},
  author={Juris J Meier and Michael A Nauck and Daniel Kranz and Jens Juul Holst and Carolyn F Deacon and Dirk Gaeckler and Wolfgang Schmidt and Baptist Gallwitz},
  journal={Diabetes},
  year={2004},
  volume={53 3},
  pages={654-62}
}
Glucagon-like peptide 1 (GLP-1) and gastric inhibitory polypeptide (GIP) are important factors in the pathogenesis of type 2 diabetes and have a promising therapeutic potential. Alterations of their secretion, in vivo degradation, and elimination in patients with chronic renal insufficiency (CRI) have not yet been characterized. Ten patients with CRI (aged 47 +/- 15 years, BMI 24.5 +/- 2.2 kg/m(2), and serum creatinine 2.18 +/- 0.86 mg/dl) and 10 matched healthy control subjects (aged 44 +/- 12… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 102 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 52 references

Similar Papers

Loading similar papers…